Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

bioAffinity Technologies, Inc. (BIAF) stock profile

bioAffinity Technologies, Inc. is a biotechnology company engaged in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath Lung, a diagnostic test for the early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Key facts

SymbolBIAF
ExchangeNASDAQ
SectorHealthcare
IndustryMedical - Diagnostics & Research
CEOMaria Zannes
Employees57
HeadquartersSan Antonio, TX, US
IPO2022-09-01
Websitewww.bioaffinitytech.com

Explore BIAF on Vantafin

  • bioAffinity Technologies, Inc. Overview
  • bioAffinity Technologies, Inc. Financials
  • bioAffinity Technologies, Inc. News
  • bioAffinity Technologies, Inc. Events
  • bioAffinity Technologies, Inc. SEC filings
  • bioAffinity Technologies, Inc. Insider transactions

Frequently asked questions

What does bioAffinity Technologies, Inc. (BIAF) do?
bioAffinity Technologies, Inc. is a biotechnology company engaged in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath Lung, a diagnostic test for the early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Where is BIAF stock listed?
bioAffinity Technologies, Inc. trades under the ticker BIAF on NASDAQ.
How can I research BIAF's financials and filings?
Vantafin provides bioAffinity Technologies, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the BIAF profile.